Literature DB >> 21217416

Acceptability of the internet-based Chlamydia screening implementation in the Netherlands and insights into nonresponse.

Katie E Greenland1, Eline L M Op de Coul, Jan E A M van Bergen, Elfi E H G Brouwers, Han J S A Fennema, Hannelore M Götz, Christian J P A Hoebe, Rik H Koekenbier, Lydia L Pars, Sander M van Ravesteijn, Ingrid V F van den Broek.   

Abstract

BACKGROUND: The study assessed the acceptability of internet-based Chlamydia screening using home-testing kits among 16- to 29-year-old participants and nonparticipants in the first year of a Chlamydia Screening Implementation program in the Netherlands.
METHODS: Questionnaire surveys were administered to randomly selected participants (acceptability survey) and nonparticipants (nonresponse survey) in 3 regions of the Netherlands where screening was offered. Participants received email invitations to an online survey; nonparticipants received postal questionnaires. Both surveys enquired into opinions on the screening design, reasons for (non-) participation and future willingness to be tested.
RESULTS: The response rate was 63% (3499/5569) in the acceptability survey and 15% (2053/13,724) in the nonresponse survey. Primary motivation for participating in the screening was "for my health" (63%). The main reason for nonresponse given by sexually active nonparticipants was "no perceived risk of infection" (40%). Only 2% reported nonparticipation due to no internet access. Participants found the internet (93%) and home-testing (97%) advantages of the program, regardless of test results. Two-thirds of participants would test again, 92% via the screening program. Half of nonparticipants were appreciative of the program design, while about 1 in 5 did not like internet usage, home-testing, or posting samples.
CONCLUSIONS: The screening method was highly acceptable to participants. Nonparticipants in this survey were generally appreciative of the program design. Both groups made informed choices about participation and surveyed low-risk nonparticipants accurately perceived their low-risk status. Although many nonparticipants were not reached by the nonresponse survey, current insights on acceptability and nonresponse are undoubtedly valuable for evaluation of the current program.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21217416     DOI: 10.1097/OLQ.0b013e318204546e

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  23 in total

1.  Evaluation of a new website design for iwantthekit for chlamydia, gonorrhea, and trichomonas screening.

Authors:  Margaret Kuder; Mary Jett Goheen; Laura Dize; Mathilda Barnes; Charlotte A Gaydos
Journal:  Sex Transm Dis       Date:  2015-05       Impact factor: 2.830

2.  Associated factors of willingness to undergo routine chlamydia trachomatis screening among hospital-based patients in Shenzhen, China: a cross-sectional study.

Authors:  Rongxing Weng; Fuchang Hong; Chunlai Zhang; Lizhang Wen; Xiangsheng Chen; Yumao Cai
Journal:  BMC Public Health       Date:  2020-11-16       Impact factor: 3.295

3.  Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation.

Authors:  Ingrid V F van den Broek; Jan E A M van Bergen; Elfi E H G Brouwers; Johannes S A Fennema; Hannelore M Götz; Christian J P A Hoebe; Rik H Koekenbier; Mirjam Kretzschmar; Eelco A B Over; Boris V Schmid; Lydia L Pars; Sander M van Ravesteijn; Marianne A B van der Sande; G Ardine de Wit; Nicola Low; Eline L M Op de Coul
Journal:  BMJ       Date:  2012-07-05

4.  Internet-based HIV and sexually transmitted infection testing in British Columbia, Canada: opinions and expectations of prospective clients.

Authors:  Travis Salway Hottes; Janine Farrell; Mark Bondyra; Devon Haag; Jean Shoveller; Mark Gilbert
Journal:  J Med Internet Res       Date:  2012-03-06       Impact factor: 5.428

5.  To develop and measure the effectiveness and acceptability of a pharmacy-based chlamydia screening intervention in Australia.

Authors:  Sajni Gudka; Lewis Marshall; Alison Creagh; Rhonda M Clifford
Journal:  BMJ Open       Date:  2013-08-17       Impact factor: 2.692

6.  Improving STD testing behavior among high-risk young adults by offering STD testing at a vocational school.

Authors:  Laura W L Spauwen; Christian J P A Hoebe; Elfi E H G Brouwers; Nicole H T M Dukers-Muijrers
Journal:  BMC Public Health       Date:  2011-09-30       Impact factor: 3.295

7.  Keeping participants on board: increasing uptake by automated respondent reminders in an Internet-based chlamydia screening in the Netherlands.

Authors:  Nynke F B Dokkum; Rik H Koekenbier; Ingrid V F van den Broek; Jan E A M van Bergen; Elfi E H G Brouwers; Johannes S A Fennema; Hannelore M Götz; Christian J P A Hoebe; Lydia L Pars; Sander M van Ravesteijn; Eline L M Op de Coul
Journal:  BMC Public Health       Date:  2012-03-09       Impact factor: 3.295

8.  Internet testing for Chlamydia trachomatis in England, 2006 to 2010.

Authors:  Sarah C Woodhall; Bersabeh Sile; Alireza Talebi; Anthony Nardone; Paula Baraitser
Journal:  BMC Public Health       Date:  2012-12-19       Impact factor: 3.295

9.  Effects of population based screening for Chlamydia infections in the Netherlands limited by declining participation rates.

Authors:  Boris V Schmid; Eelco A B Over; Ingrid V F van den Broek; Eline L M Op de Coul; Jan E A M van Bergen; Johan S A Fennema; Hannelore M Götz; Christian J P A Hoebe; G Ardine de Wit; Marianne A B van der Sande; Mirjam E E Kretzschmar
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

10.  A Web-Based Respondent Driven Sampling Pilot Targeting Young People at Risk for Chlamydia Trachomatis in Social and Sexual Networks with Testing: A Use Evaluation.

Authors:  Kevin Theunissen; Christian Hoebe; Gerjo Kok; Rik Crutzen; Chakib Kara-Zaïtri; Nanne de Vries; Jan van Bergen; Robert Hamilton; Marianne van der Sande; Nicole Dukers-Muijrers
Journal:  Int J Environ Res Public Health       Date:  2015-08-20       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.